This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of lung function, and resolution of systemic markers of inflammation and coagulation.
Drug: Adenosine
Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
Other Name: Aerogen
Inclusion Criteria:
- Adult (≥ 18 years old) male and female patients with diagnosed COVID-19 respiratory
infection, verified by culture/swab RNA. Impending ARDS respiratory collapse with
progressive increasing oxygen requirements, and in line with sub-study as defined
below.
- Patients intubated within the prior 24 hours.
- Hemodynamically stable (not requiring vasopressors or catecholamine agents to support
systemic blood pressure; no existing shock defined as BP < 100 mmHg systolic).
- In-place continuous arterial line for blood sampling.
Exclusion Criteria:
- Younger than 18 years old.
- Prisoners
- Pregnant women.
- Unable to obtain next of kin consent.
- End-stage cardiac disease with COVID-19.
- Non COVID-related causes of ARDS/respiratory failure, septic shock, or post trauma
shock, respiratory failure after blood transfusion or surgery.
- Unstable asthma or history of frequent/poorly controlled asthmatic attacks.
- Not expected to live more than 6 months due to underlying condition such as cancer.
Amy Gunnett
(352) 273-8911
agunnett@anest.ufl.edu
Bruce Spiess, Principal Investigator
University of Florida